Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04037254
Recruitment Status : Recruiting
First Posted : July 30, 2019
Last Update Posted : September 5, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
NRG Oncology

Brief Summary:
This phase II trial studies the side effects and best dose of niraparib, and to see how well it works in combination with standard of care radiation therapy and hormonal therapy (androgen deprivation therapy) in treating patients with prostate cancer that has a high chance of coming back (high risk). Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding niraparib to the usual treatments of radiation therapy and hormonal therapy may lower the chance of prostate cancer growing or returning.

Condition or disease Intervention/treatment Phase
Prostate Adenocarcinoma Stage IIC Prostate Cancer AJCC v8 Stage III Prostate Cancer AJCC v8 Stage IIIA Prostate Cancer AJCC v8 Stage IIIB Prostate Cancer AJCC v8 Stage IIIC Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Biological: Gonadotrophin Releasing Hormone Radiation: Intensity-Modulated Radiation Therapy Drug: Niraparib Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To establish the preferred dose of niraparib in combination with radiation and antiandrogen therapy (ADT). (Phase I) II. To compare the disease-free state, defined as PSA remaining < 0.1 ng/ml at the end of ADT therapy in men with high risk prostate cancer treated with standard therapy with or without the addition of niraparib. (Phase IIR)

SECONDARY OBJECTIVES:

I. To further establish the safety and toxicity profile of standard treatment with radiation and androgen deprivation therapy specifically, two years from initiation of ADT, plus niraparib at the phase II dose.

II. To compare the overall survival, prostate cancer-specific survival, local/regional or distant progression, and distant metastatic disease rates of standard therapy with or without the addition of niraparib.

EXPLORATORY OBJECTIVES:

I. To identify genomic biomarkers of response to combination therapy with radiation, ADT and PARP inhibition.

OUTLINE: This is a phase I, dose-escalation study of niraparib, followed by a phase II study.

PHASE I: Patients receive niraparib orally (PO) once daily (QD) and receive standard of care gonadotrophin releasing hormone (GnRH) agonist androgen suppression therapy. Treatment with niraparib continues for 12 months, and GnRH agonist therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib and GnRH agonist, patients undergo standard of care intensity-modulated radiation therapy (IMRT) 5 days per week for about 6-9 weeks, depending on type of radiation therapy given, in the absence of disease progression or unacceptable toxicity.

PHASE II: Patients are randomized to 1 of 2 arms:

ARM I: Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8-28 weeks after starting GnRH agonist, patients undergo IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity.

ARM II: Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months, and niraparib PO QD for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib, patients undergo standard of care IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 6 months for 3 years, then annually for 3 years.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)
Actual Study Start Date : June 3, 2019
Estimated Primary Completion Date : December 31, 2023
Estimated Study Completion Date : December 31, 2028

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Phase I (niraparib, GnRH, IMRT)
Patients receive niraparib PO QD and receive standard of care GnRH agonist androgen suppression therapy. Treatment with niraparib continues for 12 months, and GnRH agonist therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib and GnRH agonist, patients undergo standard of care IMRT 5 days per week for about 6-9 weeks, depending on type of radiation therapy given, in the absence of disease progression or unacceptable toxicity.
Biological: Gonadotrophin Releasing Hormone
Receive standard of care GnRH agonist androgen suppression therapy
Other Names:
  • AY-24031
  • D-His-6-Pro-8-NEt-LHRH
  • Follicle Stimulating Hormone-Releasing Factor
  • GN-RH
  • GnRH
  • Gonadoliberin
  • Gonadorelin
  • Gonadorelinum
  • gonadotropin-releasing hormone
  • Hoe- 471
  • LH-RF
  • LH-RH
  • LH/FSH-RF
  • LH/FSH-RH
  • LHRH
  • Luliberin
  • Luteinising Hormone-Releasing Factor
  • Luteinizing Hormone-Releasing Factor
  • luteinizing hormone-releasing hormone

Radiation: Intensity-Modulated Radiation Therapy
Undergo standard of care IMRT
Other Names:
  • IMRT
  • Intensity Modulated RT
  • Intensity-Modulated Radiotherapy

Drug: Niraparib
Given PO
Other Names:
  • MK-4827
  • MK4827

Active Comparator: Phase II, Arm I (GnRH, IMRT)
Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8-28 weeks after starting GnRH agonist, patients undergo IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity.
Biological: Gonadotrophin Releasing Hormone
Receive standard of care GnRH agonist androgen suppression therapy
Other Names:
  • AY-24031
  • D-His-6-Pro-8-NEt-LHRH
  • Follicle Stimulating Hormone-Releasing Factor
  • GN-RH
  • GnRH
  • Gonadoliberin
  • Gonadorelin
  • Gonadorelinum
  • gonadotropin-releasing hormone
  • Hoe- 471
  • LH-RF
  • LH-RH
  • LH/FSH-RF
  • LH/FSH-RH
  • LHRH
  • Luliberin
  • Luteinising Hormone-Releasing Factor
  • Luteinizing Hormone-Releasing Factor
  • luteinizing hormone-releasing hormone

Radiation: Intensity-Modulated Radiation Therapy
Undergo standard of care IMRT
Other Names:
  • IMRT
  • Intensity Modulated RT
  • Intensity-Modulated Radiotherapy

Experimental: Phase II, Arm II (niraparib, GnRH, IMRT)
Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months, and niraparib PO QD for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib, patients undergo standard of care IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity.
Biological: Gonadotrophin Releasing Hormone
Receive standard of care GnRH agonist androgen suppression therapy
Other Names:
  • AY-24031
  • D-His-6-Pro-8-NEt-LHRH
  • Follicle Stimulating Hormone-Releasing Factor
  • GN-RH
  • GnRH
  • Gonadoliberin
  • Gonadorelin
  • Gonadorelinum
  • gonadotropin-releasing hormone
  • Hoe- 471
  • LH-RF
  • LH-RH
  • LH/FSH-RF
  • LH/FSH-RH
  • LHRH
  • Luliberin
  • Luteinising Hormone-Releasing Factor
  • Luteinizing Hormone-Releasing Factor
  • luteinizing hormone-releasing hormone

Radiation: Intensity-Modulated Radiation Therapy
Undergo standard of care IMRT
Other Names:
  • IMRT
  • Intensity Modulated RT
  • Intensity-Modulated Radiotherapy

Drug: Niraparib
Given PO
Other Names:
  • MK-4827
  • MK4827




Primary Outcome Measures :
  1. Maintenance of disease-free state [ Time Frame: Up to 2 years following the start of antiandrogen therapy ]
    Will be characterized by PSA values sustained below 0.1 ng/ml. A modified intent-to-treat analysis will be conducted. The proportion of patients disease-free at 24 months will be compared in the two treatment arms using a non continuity-corrected chi-square test. As a secondary analysis, a logistic regression model will be fit to adjust for the stratification factors (risk group and type of radiation therapy).


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: From randomization until death from any cause, assessed up to 3 years ]
    Will consist of comparison of Kaplan-Meier (Kaplan 1958) curves using a logrank test.

  2. Prostate cancer-specific survival [ Time Frame: From randomization until death from prostate cancer, assessed up to 3 years ]
    Will consist of comparison of Kaplan-Meier (Kaplan 1958) curves using a logrank test.

  3. Pathologic complete response (pCR) [ Time Frame: At 24 months ]
    Will be assessed among patients undergoing 12-core biopsy. Will be compared using a chi-square test.

  4. Time to local/regional or distant progression [ Time Frame: Up to 3 years ]
    Cumulative incidence curves will be compared using the Fine-Gray test (Dignam 2008).

  5. Time to distant metastases [ Time Frame: From randomization until detection of distant metastatic disease, assessed up to 3 years ]
    Cumulative incidence curves will be compared using the Fine-Gray test (Dignam 2008).

  6. Biochemical progression-free survival [ Time Frame: Up to 3 years ]
    Will be defined as PSA >= 2 ng/ml over the nadir PSA, the presence of local, regional, or distant recurrence, or death from prostate cancer. Will consist of comparison of Kaplan-Meier (Kaplan 1958) curves using a logrank test.

  7. Incidence of adverse events (Phase II) [ Time Frame: Up to 3 years ]
    Adverse event (AE) rates in the two treatment arms will be summarized by time of occurrence (early versus late), type, grade, and attribution to treatment. For each type of AE, the worst grade occurring during the early treatment period, late treatment period, or entire treatment period will be determined. For each time period, treatment group comparisons will be conducted using chi-square or Fisher exact tests.


Other Outcome Measures:
  1. Exome sequencing of deoxyribonucleic acid (DNA) repair genes and detected alterations [ Time Frame: Up to 3 years ]
    Descriptive statistics will be generated summarizing the frequency of gene alterations, mutations, and gene expression levels. The percentage of patients with baseline or post-therapy alterations in targeted genes will be reported and the association between the occurrence of reversion mutations in DNA repair genes and clinical outcomes will be assessed using logistic regression models for dichotomous endpoints (disease-free state, pCR), and Cox regression or competing risk regression modeling for time-to-event data.

  2. Transcription-wide analysis of gene expression [ Time Frame: Up to 3 years ]
    Will be assessed using a high-density Affymetrix oligonucleotide array to profile the transcriptome of tumor samples. Descriptive statistics will be generated summarizing the frequency of gene alterations, mutations, and gene expression levels. The percentage of patients with baseline or post-therapy alterations in targeted genes will be reported and the association between the occurrence of reversion mutations in DNA repair genes and clinical outcomes will be assessed using logistic regression models for dichotomous endpoints (disease-free state, pCR), and Cox regression or competing risk regression modeling for time-to-event data.

  3. Single nucleotide polymorphisms [ Time Frame: Up to 3 years ]
    Will be analyzed in whole blood samples previously associated with prostate risk. Plasma samples will be assessed for baseline and post-therapy alterations in a targeted gene panel and for reversion mutations in DNA repair genes as early biomarkers of treatment resistance. Descriptive statistics will be generated summarizing the frequency of gene alterations, mutations, and gene expression levels. The percentage of patients with baseline or post-therapy alterations in targeted genes will be reported and the association between the occurrence of reversion mutations in DNA repair genes and clinical outcomes will be assessed using logistic regression models for dichotomous endpoints (disease-free state, pCR), and Cox regression or competing risk regression modeling for time-to-event data.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed (within 180 days prior to registration) adenocarcinoma of the prostate at high risk for recurrence as determined by the following criteria, according to American Joint Committee on Cancer (AJCC) 8th edition:

    • Phase I enrollment

      • Gleason >= 9, PSA =< 150 ng/mL, any T-stage
    • Phase II enrollment

      • Gleason >= 9, PSA =< 150 ng/mL, any T-stage
      • Gleason 8, PSA < 20 ng/mL, and >= T2
      • Gleason 8, PSA >= 20-150 ng/mL, any T-stage
      • Gleason 7, PSA >= 20-150 ng/mL, any T-stage
  • No distant metastases as evaluated by:

    • Bone scan 90 days prior to registration
    • Lymph node assessment by computed tomography (CT) or magnetic resonance (MR) of pelvis or nodal sampling within 90 days prior to registration (Please note: Lymph nodes will be considered negative (N0) if they are < 1.5 cm short axis)
  • History/physical examination within 90 days prior to registration
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 180 days prior to registration
  • Pretreatment serum PSA, obtained prior to any androgen suppression therapy and within 180 days of registration
  • Phase I patients: Prior androgen suppression for prostate cancer is not allowed prior to registration
  • Phase II patients: Prior androgen suppression for prostate cancer is allowed =< 45 days prior to registration
  • Hemoglobin >= 9.0 g/dL (within 90 days prior to registration)
  • Platelets >= 100,000 cells/mm^3 (within 90 days prior to registration)
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (within 90 days prior to registration)
  • Serum creatinine =<1.5 x upper limit of normal (ULN) OR a calculated creatinine clearance >= 60 mL/min estimated using Cockcroft-Gault equation (within 90 days prior to registration)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN (within 90 days prior to registration)
  • Serum albumin >= 3 g/dL (within 90 days prior to registration)
  • Serum potassium >= 3.5 mg/dL (within 90 days prior to registration)
  • Serum total bilirubin =< 1.5 x ULN or direct bilirubin =< 1 x ULN (Note: in subjects with Gilberts syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin, and if direct bilirubin is =< 1.5 x ULN, subject may be eligible) (within 90 days prior to registration)
  • Men of child-producing potential must be willing to consent to use effective contraception while on treatment and for at least 3 months afterwards
  • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry

Exclusion Criteria:

  • PSA > 150 ng/mL
  • Definitive clinical or radiologic evidence of metastatic disease
  • Pathologically positive lymph nodes or nodes > 1.5 cm short axis on CT or MR imaging
  • Prior radical prostatectomy, cryosurgery for prostate cancer, or bilateral orchiectomy for any reason
  • Any active malignancy within 2 years of study registration that may alter the course of prostate cancer treatment
  • Prior systemic therapy for prostate cancer; note that prior therapy for a different cancer is allowable
  • Prior radiotherapy, including brachytherapy, to the region of the prostate that would result in overlap of radiation therapy fields
  • Current treatment with first generation anti-androgens (bicalutamide, nilutamide, flutamide). For patients enrolled to phase II, if prior anti-androgens were administered, a washout period of >= 30 days is required prior to enrollment
  • Severe, active co-morbidity, defined as follows:

    • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
    • Transmural myocardial infarction within the last 6 months
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
    • Uncontrolled acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition
    • Presence of uncontrolled hypertension (persistent systolic blood pressure [BP] >=160 mmHg or diastolic BP >= 100 mmHg). Subjects with a history of hypertension are allowed, provided that BP is controlled to within these limits by anti-hypertensive treatment
  • Prior allergic reaction to the drugs involved in this protocol
  • Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter

    • Note that patients who are HIV positive are eligible, provided they have a CD4 count >= 200 cells/microliter within 90 days prior to registration. Patients receiving treatment with highly active antiretroviral therapy (HAART) will not be eligible due to concern for radiosensitization
    • Note also that HIV testing is not required for eligibility for this protocol. This exclusion criterion is necessary because the treatments involved in this protocol may be affected by these drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04037254


Locations
Layout table for location information
United States, Illinois
Carle Cancer Center Recruiting
Urbana, Illinois, United States, 61801
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Vamsi K. Vasireddy         
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Site Public Contact    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Brian C. Baumann         
Siteman Cancer Center-South County Recruiting
Saint Louis, Missouri, United States, 63129
Contact: Site Public Contact    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Brian C. Baumann         
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Site Public Contact    405-271-8777    ou-clinical-trials@ouhsc.edu   
Principal Investigator: Christina Henson         
United States, South Carolina
Saint Francis Cancer Center Recruiting
Greenville, South Carolina, United States, 29607
Contact: Site Public Contact    864-603-6213    meissa_beckman@bshsi.org   
Principal Investigator: Robert D. Siegel         
Sponsors and Collaborators
NRG Oncology
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: M. D Michaelson NRG Oncology

Layout table for additonal information
Responsible Party: NRG Oncology
ClinicalTrials.gov Identifier: NCT04037254     History of Changes
Other Study ID Numbers: NRG-GU007
NCI-2019-02260 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
NRG-GU007 ( Other Identifier: NRG Oncology )
NRG-GU007 ( Other Identifier: CTEP )
U10CA180868 ( U.S. NIH Grant/Contract )
First Posted: July 30, 2019    Key Record Dates
Last Update Posted: September 5, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Adenocarcinoma
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Niraparib
Hormones
Follicle Stimulating Hormone
Androgens
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors